{"id":"W3030001291","doi":"10.1200/jco.2020.38.15_suppl.5516","title":"Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Clinical endpoint; Abiraterone acetate; Urology; Androgen deprivation therapy; Doubling time; Tolerability; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001891901,0.001238306,0.001552131,0.0003990141,0.000286457,0.0006482982,0.0006761173,0.0007482936,0.003807293],"category_scores_gemma":[0.00128013,0.0004187422,0.001721373,0.0002960017,0.0006926328,0.0006202955,0.0003393571,0.002253989,0.0005244344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006574371,"about_ca_system_score_gemma":0.0008155121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006661149,"about_ca_topic_score_gemma":0.001821842,"domain_scores_codex":[0.9995054,0.0002711933,0.00003691112,0.00007540518,0.00004946305,0.00006157033],"domain_scores_gemma":[0.9991779,0.0001858326,0.0002036547,0.00007115262,0.00004692986,0.0003145538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9031925,0.01717272,0.003697468,0.0007390587,0.00199732,0.00008235103,0.0001731929,0.001555696,0.01253759,0.0001729112,0.001280757,0.05739835],"study_design_scores_gemma":[0.5020923,0.4764371,0.01412101,0.00004446301,0.001789353,0.0001999994,0.00005083131,0.0007701743,0.002826922,0.0002729189,0.001368723,0.00002625796],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948344,0.001576273,0.0003278865,0.0001336765,0.00007180722,0.0008347888,0.0009008705,0.00004524749,0.001275119],"genre_scores_gemma":[0.9941169,0.00105943,0.0007239039,0.0002872148,0.00007912845,0.0006794283,0.00144899,0.00001572369,0.001589298],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003807293,"threshold_uncertainty_score":0.01273674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2538544650300776,"score_gpt":0.4959335255756794,"score_spread":0.2420790605456018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}